Tivantinib
Tivantinib
Tivantinib (pronounced ti-van-ti-nib) is an experimental cancer drug that is being studied for its potential use in the treatment of various types of cancer, including hepatocellular carcinoma (HCC), non-small cell lung cancer (NSCLC), and colorectal cancer (CRC).
Etymology
The name "Tivantinib" is derived from the combination of the prefix "Tivan-", which is a proprietary designation, and the suffix "-tinib", which is commonly used in the names of tyrosine kinase inhibitors (TKIs). The "-tinib" suffix indicates that the drug works by inhibiting the activity of one or more tyrosine kinases, enzymes that play a key role in the signaling pathways that regulate cellular processes such as growth, division, and death.
Mechanism of Action
Tivantinib is a non-ATP competitive inhibitor of the c-Met receptor tyrosine kinase. By inhibiting c-Met, Tivantinib disrupts the signaling pathways that promote cancer cell growth and survival, thereby potentially slowing or stopping the progression of the disease.
Clinical Trials
Tivantinib has been evaluated in several clinical trials, including a Phase III trial for HCC, a Phase II trial for NSCLC, and a Phase I trial for CRC. The results of these trials have shown promise, but further research is needed to fully understand the drug's efficacy and safety profile.
Related Terms
- Tyrosine kinase inhibitors (TKIs)
- Hepatocellular carcinoma (HCC)
- Non-small cell lung cancer (NSCLC)
- Colorectal cancer (CRC)
- c-Met
- ATP
- Clinical trials
External links
- Medical encyclopedia article on Tivantinib
- Wikipedia's article - Tivantinib
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski